Prochymal FDA Approval Status
FDA Approved: No
Brand name: Prochymal
Company: Osiris Therapeutics, Inc.
Treatment for: Graft-versus-host disease
Prochymal is a preparation of mesenchymal stem cells formulated for intravenous infusion. Prochymal is currently being evaluated in Phase III trials for steroid refractory graft-versus-host disease (GvHD), acute GvHD, and Crohn's disease.
Development timeline for Prochymal
| Date | Article |
|---|---|
| Jan 15, 2009 | Osiris and FDA Reach Agreement on Submission of First Marketing Application for a Stem Cell Product |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
